Aviex Technologies LLC was founded
to develop a novel vaccine platform delivery technology for infectious diseases.

Features and Benefits
of the new platform delivery technology:

About Us

Aviex Technologies LLC (Aviex) is an infectious disease vaccine development company using the enhanced Salmonella YS1646 vector. The company has initially undertaken the development of three high value vaccines relating to diseases that take a high toll in human suffering often causing disability or death.

The three primary pathogens in which Aviex has demonstrated its platform delivery technology are Clostridium difficile, a bacterial disease of the gut initially limited to hospitals and now spreading throughout the general population. There are no licensed vaccines to prevent C. difficile. The second is an oral parasitic vaccine for Schistosoma mansoni; an important global neglected tropical disease potentially affecting 700 million people on three continents. The third is a vaccine for Cryptosporidium parvum, a disease affecting both human and animal health, which has a high mortality rate.

The Company is led by American entrepreneur Joel B. Grae, who has assembled first rate scientific, medical and managerial teams. He is the Founder or Co-Founder of 6 prior companies in the medical, pharmaceutical, life science and nuclear industries. Grae is a lawyer and an inventor who holds 7 issued patents.

Brian J. Ward MD, MSc is the principal Investigator. He is a Professor of Medicine and Microbiology at McGill University, Co-Director-McGill University Health Centre, Vaccine Research Unit, and Medical Director-National Reference Centre for Parasitology.